3 Unstoppable Dividend Stocks to Buy in a Potential Market Sell-Off
Major market indexes hover NEAR all-time highs as investors celebrate the Federal Reserve's recent rate cut. Yet historical valuations and economic uncertainty suggest a correction could loom by early 2026. Market downturns, however, often unveil opportunities.
AbbVie (ABBV) presents a compelling case. Despite a sky-high trailing P/E of 103, its forward earnings multiple of 15 and PEG ratio of 0.39 signal undervaluation. The biopharma's growth pipeline justifies optimism, with analysts projecting robust earnings expansion.